Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorKU Leuven
About this trial
The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.
The main question it aims to answer are:
* Which diagnostic modality is preferred by patients and the general population? * Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality? * Are geographical differences present in regard to the preference for a diagnostic modality?
Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individuals >18yo to 75yo (upper age limit of Barrett's surveillance)
Access to computer or smartphone
Clear understanding of available languages of the experiment (English, French, Dutch, Spanish, German, Chinese, Japanese)
Disqualifiers
Individuals less than 18yo and more than 75yo
Incarcerated individuals
Trial design
Design model
Single group
Treatments tested in this trial
Survey
Other interventionDiscrete choice survey
Treatment groups
2,200 Participants
are divided into 1 treatment groupGroup A: Survey participantsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
The rate of contribution of diagnostic features to the preference of participants
A part-worth analysis, expressed as percentage, from a discrete choice experiment (questionnaire) will assess the features that are most important to the participants
Time frame
2 years2
The percentage differences in preference of participants between geographical regions
Differences in preferences will be compared between different geographical regions using chi-squared or McNemar's test
Time frame
2 yearsSecondary outcomes
1
Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio
Assess the influence of demographic characteristics on the decision-making process using a multivariable logistic regression model, providing odds ratios.
Time frame
2 years2
Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs
Based on an anticipated cancer detection and cost, we will assess the willingness-to-pay using a multivariable logistic regression, providing odds ratios.
Time frame
2 years Source ClinicalTrials.gov